Influenza A virus vaccine H7N9 - sanofi pasteur

Drug Profile

Influenza A virus vaccine H7N9 - sanofi pasteur

Alternative Names: A/H7N9 virus vaccine

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator sanofi pasteur
  • Developer National Institute of Allergy and Infectious Diseases; Sanofi Pasteur
  • Class Influenza A vaccines; Influenza A virus H7N9 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H7N9 subtype

Most Recent Events

  • 29 Sep 2016 National Institute of Allergy and Infectious Diseases plans a phase II trial for Influenza-A virus H7N9 subtype (Prevention, In adults) in USA (IM) (NCT02921997)
  • 01 Jul 2016 National Institute of Allergy and Infectious Diseases completes a phase II trial for Influenza-A virus H7N9 subtype (In the elderly, Prevention) in USA (IM) (NCT02213354)
  • 01 Mar 2016 Phase-II development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top